Monday, 11 May 2015 10:09

Biosimilar reimbursement pathways: CMS guidance and outstanding issues

Written by 
Rate this item
(1 Vote)
The Centers for Medicare & Medicaid Services (CMS) recently issued three guidances regarding reimbursement for biosimilars under Medicare Parts B and D, as well as under Medicaid. These guidances address questions that have arisen regarding reimbursement policies that CMS will implement for biosimilars.
Read 120487 times

 
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1

IN THE NODE

Updates

 knowyoursubtype iconb   facebook2 twitter2 youtube1 Contact Us 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.